OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 6125-6132

  Humphreys, Ian R ^a   Edwards, Lorna ^a   Walzl, Gerhard ^a   Rae, Aaron J ^a   Dougan, Gordon ^a   Hill, Sue ^b   Hussell, Tracy ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD134 LIGAND; CD134 LIGAND IMMUNOGLOBULIN FUSION PROTEIN; CD28 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EOSINOPHIL; EOSINOPHILIA; FEMALE; LIGAND BINDING; LOEFFLER PNEUMONIA; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOLECULAR INTERACTION; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL;

EID: 0038619067     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.6125     Document Type: Article

References (64)

1. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14233:58.
2. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286.
3. Carreno, B. M., and M. Collins. 1902. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29.
4. Calderhead, D. M., J. E. Buhlmann, A. J. van-den-Eertwegh, E. Claassen, R. J. Noelle, and H. P. Fell. 1993. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol. 151:5261.
5. Gramaglia, I., A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:3043.
6. Birkeland, M. L., N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and A. N. Barclay. 1995. Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein. Eur. J. Immunol. 25:926.
7. Akiba, H., H. Oshima, K. Takeda, M. Atsuta, H. Nakano, A. Nakajima, C. Nohara, H. Yagita, and K. Okumura. 1999. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 162:7058.
8. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510.
9. + T cells with homology to tumor necrosis factor. J. Exp. Med. 180:757.
10. Pippig, S. D., C. Pena-Rossi, J. Long, W. R. Godfrey, D. J. Fowell, S. L. Reiner, M. L. Birkeland, R. M. Locksley, A. N. Barclay, and N. Killeen. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163:6520.
11. Kopf, M., C. Ruedl, N. Schmitz, A. Gallimore, K. Lefrang, B. Ecabert, B. Odermatt, and M. F. Bachmann. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11:699.
12. Murata, K., N. Ishii, H. Takano, S. Miura, L. C. Ndhlovu, M. Nose, T. Noda, and K. Sugamura. 2000. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191:365.
13. Chen, A. I., A. J. McAdam, J. E. Buhlmann, S. Scott, M. L. Lupher, E. A. Greenfield, P. R. Baum, W. C. Fanslow, D. M. Calderhead, G. J. Freeman, and A. H. Sharpe. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 11:689.
14. Maxwell, J. R., A. Weinberg, R. A. Prell, and A. T. Vella. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164:10Z
15. Bansal-Pakala, P., A. G. Jember, and M. Croft. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907.
16. + T cells into high IL-4-producing effectors. Blood 92:3338.
17. Flynn, S., K. M. Toellner, C. Raykundalia, M. Goodall, and P. Lane. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and up-regulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297.
18. Akiba, H., Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191:375.
19. Marwaha, R. K., A. Trehan, K. Jayashree, and R. K. Vasishta. 1995. Hypereosinophilia in disseminated cryptococcal disease. Pediatr. Infect. Dis. J. 14:1102.
20. Ando, M., M. Suga, Y. Nishiura, and M. Miyajima. 1995. Summer-type hypersensitivity pneumonitis. Intern Med. 34:707.
21. Levitz, S. M. 1991. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev. Infect. Dis. 13:1163.
22. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19:1029.
23. + T cells. J. Exp. Med. 173:755.
24. + T cells. J. Exp. Med. 173:793.
25. Huffnagle, G. B., J. L. Yates, and M. F. Lipscomb. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59:1423.
26. + T cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans. J. Lab. Clin. Med. 121:765.
27. Horn, C. A., and R. G. Washburn. 1995. Anticryptococcal activity of NK cellenriched peripheral blood lymphocytes from human immunodeficiency virusinfected subjects: responses to interleukin-2, interferon-γ, and interleukin-12. J. Infect. Dis. 172:1023.
28. Collins, H. L., and G. J. Bancroft. 1992. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur. J. Immunol. 22:1447.
29. Yuan, R. R., A. Casadevall, J. Oh, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94:2483.
30. Decken, K., G. Kohler, K. Palmer-Lehmann, A. Wunderlin, F. Matmer, J. Magram, M. K. Gately, and G. Alber. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66:4994.
31. Kawakami, K., M. H. Qureshi, T. Zhang, Y. Koguchi, S. Yara, K. Takeda, S. Akira, M. Kurimoto, and A. Saito. 2000. Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice. FEMS Immunol. Med. Microbiol. 27:191.
32. Huffnagle, G. B., M. B. Boyd, N. E. Street, and M. F. Lipscomb. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160:2393.
33. Feldmesser, M., Y. Kress, and A. Casadevall. 1998. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis. 177:1639.
34. Costa, J. J., K. Matossian, M. B. Resnick, W. J. Beil, D. T. Wong, J. R. Gordon, A. M. Dvorak, P. F. Weller, and S. J. Galli. 1993. Human eosinophils can express the cytokines tumor necrosis factor-a and macrophage inflammatory protein-1α. J. Clin. Invest. 91:2673.
35. Al-Shamkhani, A., M. L. Birkeland, M. Puklavec, M. H. Brown, W. James, and A. N. Barclay. 1996. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26:1695.
36. Weinberg, A. D., M. M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2160.
37. Hussell, T., L. C. Spender, A. Georgiou, A. O'Garra, and P. J. M. Openshaw. 1996. Th1 and Th2 cytokine induction in pulmonary T-cells during infection with respiratory syncytial virus. J Gen. Virol. 77:2447.
38. Lloyd, C. M., A. O. Wozencraft, and D. G. Williams. 1993. Cell-mediated pathology during murine malaria-associated nephritis. Clin. Exp. Immunol. 94:398.
39. Seko, Y., N. Takahashi, H. Oshima, O. Shimozato, H. Akiba, K. Takeda, T. Kobata, H. Yagita, K. Okumura, M. Azuma, and R. Nagai. 2001. Expression of tumor necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3. J. Pathol. 195:593.
40. Malmstrom, V., D. Shipton, B. Singh, A. Al-Shamkhani, M. J. Puklavec, A. N. Barclay, and F. Powrie. 2001. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J. Immunol. 166:6972.
41. Brocker, T., A. Gulbranson-Judge, S. Flynn, M. Riedinger, C. Raykundalia, and P. Lane. 1999. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29:1610.
42. Walker, L. S., A. Gulbranson-Judge, S. Flynn, T. Brocker, C. Raykundalia, M. Goodall, R. Forster, M. Lipp, and P. Lane. 1999. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190:1115.
43. De-Smedt, T., J. Smith, P. Baum, W. Fanslow, E. Butz, and C. Maliszewski. 2002. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168:661.
44. Pietrella, D., S. Perito, F. Bistoni, and A. Vecchiarelli. 2001. Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans. Infect. Immun. 69:1508.
45. McGaha, T., and J. W. Murphy. 2000. CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect. Immun. 68:4624.
46. L and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15:445.
47. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J. Immunol. 167:6804.
48. Imura, A., T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama. 1996. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp. Med. 183:2185.
49. Imura, A., T. Hori, K. Imada, S. Kawamata, Y. Tanaka, S. Imamura, and T. Uchiyama. 1997. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 89:2951.
50. Luttmann, W., E. Dauer, S. Schmidt, O. Marx, M. Hossfeld, H. Matthys, and J.-C. J. Virchow. 2000. Effects of interferon-α and tumor necrosis factor-α on CD95/Fas ligand-mediated apoptosis in human blood eosinophils. Scand. J. Immunol. 51:54.
51. Shi, H.-Z., A. Humbles, C. Gerard, Z. Jin, and P. F. Weller. 2000. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J. Clin. Invest. 105:945.
52. Rogers, P. R., and M. Croft. 2000. CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol. 164:2955.
53. + intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cellmediated cytotoxicity, IFN-γ, and IL-10 regulation. Immunol. 167:6717.
54. Flesch, I. E., G. Schwamberger, and S. H. Kaufmann. 1989. Fungicidal activity of IFN-γ-activated macrophages: extracellular killing of Cryptococcus neoformans. J. Immunol. 142:3219.
55. Mody, C. H., C. L. Tyler, R. G. Sitrin, C. Jackson, and G. B. Toews. 1991. Interferon-γ activates rat alveolar macrophages for anticryptococcal activity. Am. J. Respir. Cell Mol. Biol. 5:19.
56. Kawakami, K., Y. Koguchi, M. H. Qureshi, S. Yara, Y. Kinjo, A. Miyazato, A. Nishizawa, H. Nariuchi, and A. Saito. 2000. Circulating soluble CD4 directly prevents host resistance and delayed-type hypersensitivity response to Cryptococcus neoformans in mice. Microbiol. Immunol. 44:1033.
57. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukocyte Biol. 55:35.
58. Retini, C., A. Casadevall, D. Pietrella, C. Monari, B. Palazzetti, and A. Vecchiarelli. 1999. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J. Immunol. 162:1618.
59. Armitage, R. J., W. C. Fanslow, L. Strockbine, T. A. Sato, K. N. Clifford, B. M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, et al. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80.
60. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, and T. R. Kozel. 2000. T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur. J. Immunol. 30:1385.
61. Stuber, E., and W. Strober. 1996. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J. Exp. Med. 183:979.
62. Morimoto, S., Y. Kanno, Y. Tanaka, Y. Tokano, H. Hashimoto, S. Jacquot, C. Morimoto, S. F. Schlossman, H. Yagita, K. Okumura, and T. Kobata. 2000. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J. Immunol. 164:4097.
63. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:495.
64. Weinberg, A. D. 2002. OX40: targeted immunotherapy: implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 23:102.